Abstract
INTRODUCTION
Anti-amyloid therapies can slow Alzheimer’s disease (AD) progression; diagnostic and treatment delays might reduce their value.
METHODS
Using dynamic microsimulation, we estimated the gross societal value of anti-amyloid treatment for Americans with early symptomatic AD. A treatment scenario slowed the rate of clinical progression by 29% over individuals’ remaining lifetime (baseline mean age: 73.0); earlier treatment initiated 2 years earlier.
RESULTS
Treatment generated $104,885 (95% CI: $99,291, $110,479) in gross societal value over an individual’s lifetime, including quality-of-life gains, reduced caregiving burden, and medical cost offsets driven by reduced nursing home use and Medicaid spending. Earlier treatment increased value 32%; this rose to 71% if treatment effects are also stronger (36% slowing) in earlier AD stages. Scenarios with 4-year effect duration yielded $49,122 (treatment) and $56,385 (earlier treatment).
DISCUSSION
Timely treatment consistently increased long-term societal value. The findings provide a benchmark against which treatment implementation costs can be weighed.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: | October 7, 2026
Neuro-Dementia